Experimental and bioinformatic characterisation of the promoter region of the Marfan syndrome gene, FBN1.
Mutations in the FBN1 gene, encoding the extracellular matrix protein fibrillin-1, result in the dominant connective tissue disease Marfan syndrome. Marfan syndrome has a variable phenotype, even within families carrying the same FBN1 mutation. Differences in gene expression resulting from sequence differences in the promoter region of the FBN1 gene are likely to be involved in causing this phenotypic variability. In this report, we present an analysis of FBN1 transcription start site (TSS) use in mouse and human tissues. We found that transcription of FBN1 initiated primarily from a single CpG-rich promoter which was highly conserved in mammals. It contained potential binding sites for a number of factors implicated in mesenchyme differentiation and gene expression. The human osteosarcoma line MG63 had high levels of FBN1 mRNA and secreted fibrillin-1 protein to form extracellular matrix fibres. The human embryonic kidney line HEK293 and two breast cancer lines MCF7 and MDA-MB-231 had levels of FBN1 mRNA 1000 fold lower and produced negligible amounts of fibrillin-1 protein. Therefore MG63 appears to be the optimal cell line for examining tissue-specific, biologically relevant promoter activity for FBN1. In reporter assays, the conserved promoter region was more active in MG63 cells than in non-FBN1-expressing lines but additional elements outside the proximal promoter are probably required for optimal tissue-specific expression. Understanding the regulation of the FBN1 gene may lead to alternative therapeutic strategies for Marfan syndrome.
Summers
Kim M
KM
The University of Edinburgh, The Roslin Institute and Royal (Dick) School of Veterinary Studies, Roslin, Midlothian EH25 9PS, UK. kim.summers@roslin.ed.ac.uk
Bokil
Nilesh J
NJ
Baisden
John M
JM
West
Malcolm J
MJ
Sweet
Matthew J
MJ
Raggatt
Liza J
LJ
Hume
David A
DA
D000818:Animals; D020029:Base Pairing; D001483:Base Sequence; D001665:Binding Sites; D002460:Cell Line; D045744:Cell Line, Tumor; D019295:Computational Biology / Q000379:methods*; D018899:CpG Islands; D005091:Exons; D000071838:Fibrillin-1; D000071837:Fibrillins; D005455:Fluorescent Antibody Technique; D005799:Genes, Dominant; D017930:Genes, Reporter; D006801:Humans; D007150:Immunohistochemistry; D007668:Kidney / Q000166:cytology; D008156:Luciferases / Q000378:metabolism; D008382:Marfan Syndrome / Q000235:genetics*; D051379:Mice; D008840:Microfilament Proteins / Q000235:genetics*; D008969:Molecular Sequence Data; D010006:Osteoblasts / Q000378:metabolism; D011401:Promoter Regions, Genetic; D011485:Protein Binding; D012333:RNA, Messenger / Q000378:metabolism; D020539:Sequence Analysis, Protein; D024363:Transcription Initiation Site; D054392:Adipokines
D000071838:Fibrillin-1; D000071837:Fibrillins; D008156:Luciferases; D008840:Microfilament Proteins; D012333:RNA, Messenger; C000605722:FBN1 protein, human; D054392:Adipokines; C000605724:Fbn1 protein, mouse